Black Rock Inc. Reviva Pharmaceuticals Holdings, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Reviva Pharmaceuticals Holdings, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 102,932 shares of RVPH stock, worth $130,723. This represents 0.0% of its overall portfolio holdings.

Number of Shares

102,932

Previous 91,861 12.05%

Holding current value

$130,723

Previous $347,000 62.25%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.25 - $3.79 $13,838 - $41,959	11,071 Added 12.05%	102,932 $131,000
Q1 2024 May 10, 2024	SELL	$2.76 - $5.52 $1,040 - $2,081	-377 Reduced 0.41%	91,861 $347,000
Q4 2023 Feb 13, 2024	BUY	$3.56 - $6.04 $12,630 - $21,429	3,548 Added 4.0%	92,238 $475,000
Q3 2023 Nov 13, 2023	SELL	$3.91 - $5.9 $5,145 - $7,764	-1,316 Reduced 1.46%	88,690 $432,000
Q2 2023 Aug 11, 2023	BUY	$4.42 - $8.55 $22,329 - $43,194	5,052 Added 5.95%	90,006 $527,000
Q4 2022 Feb 13, 2023	BUY	$1.68 - $5.99 $2,187 - $7,798	1,302 Added 1.56%	84,954 $361,000
Q3 2022 Nov 14, 2022	BUY	$0.14 - $2.66 $11,711 - $222,514	83,652 New	83,652 $133,000
Q2 2022 Aug 12, 2022	SELL	$1.03 - $2.47 $23,527 - $56,419	-22,842 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$1.61 - $3.01 $3,210 - $6,001	-1,994 Reduced 8.03%	22,842 $56,000
Q4 2021 Feb 10, 2022	SELL	$2.7 - $4.23 $23,311 - $36,521	-8,634 Reduced 25.8%	24,836 $71,000
Q3 2021 Nov 09, 2021	BUY	$3.29 - $4.79 $49,850 - $72,578	15,152 Added 82.72%	33,470 $136,000
Q2 2021 Aug 11, 2021	BUY	$4.05 - $8.7 $74,187 - $159,366	18,318 New	18,318 $89,000

Others Institutions Holding RVPH

# of Institutions

Shares Held

9.97M

Call Options Held

133K

Put Options Held

43.9K

View Full List

About REVIVA PHARMACEUTICALS HOLDINGS, INC.

Ticker RVPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,442,900
Market Cap $26M
Description
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP506...

More about RVPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account